Navigation Links
Alexza Reports 2008 Year-End Financial Results and Updates Clinical Pipeline Status
Date:3/10/2009

measured at 2 hours after the first dose. Both the 5 mg and 10 mg doses of AZ-004 met these primary and secondary endpoints. All results were considered statistically significant at the p < 0.05 level, as compared to placebo, and all statistical analyses were made on an intent-to-treat basis. The 10 mg dose of AZ-004 exhibited a rapid onset of effect, with statistically significant reduction in agitation at 10 minutes post-dose, the first time point measure in the study. The reduction of agitation was generally sustained through the 24-hour study period. Various additional assessments of a patient's agitation state were conducted at serial time points using the PEC score over the first 4-hour post-dose time period, with follow-up assessments at the end of the 24-hour study period. Side effects were recorded for each patient throughout the clinical trial period. The administration of AZ-004 was generally safe and well tolerated. The most common side effect, and the only side effect reported by at least 10% of the patients in any treatment group, was taste. This side effect was rated as mild in all patients.

In September 2008, the Company announced positive results from its first Phase 3 clinical trial of AZ-004 in 344 acutely agitated schizophrenic patients. The study design was similar to the clinical trial outlined above. Both the 5 mg and the 10 mg doses of AZ-004 met the primary and secondary endpoints of the study. The administration of AZ-004 was generally safe and well tolerated in this patient population.

AZ-004 has been licensed to Symphony Allegro, Inc., or Symphony Allegro, and the Company has the right to repurchase all rights to this product candidate.

  • AZ-104 (Staccato loxapine). Alexza is developing AZ-104 to treat patients suffering from acute migraine headaches. AZ-104 is a lower dose version of AZ-004. In January 2009, Alexza initiated an AZ-104 outpati
    '/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine news :

1. Alexzas Corporate Presentation to be Webcast at the Cowen & Company 29th Annual Health Care Conference
2. Alexza to Announce 2008 Financial Results and Update Its Clinical Pipeline on Tuesday, March 10, 2009
3. Alexza Pharmaceuticals Promotes Peter D. Noymer, PhD to Vice President, Product R&D
4. Alexza Pharmaceuticals Announces Upcoming Conference Participation and Webcasts
5. Alexza Reports 2008 Third Quarter Financial Results and Updates Development of Product Candidates
6. Alexza to Announce 2008 Third Quarter Financial Results and Update Its Clinical Pipeline on Thursday, November 6, 2008
7. Anthony Clarke, PhD Joins Alexza Pharmaceuticals as Vice President, International Development Operations
8. Jeffrey S. Williams Rejoins Alexza Pharmaceuticals as President, Alexza Singapore Pte. Ltd.
9. Carlos A. Parra Joins Alexza Pharmaceuticals as Vice President, Quality
10. Alexzas Corporate Presentation to be Webcast at the Seventh Annual JMP Securities Research Conference and the 2008 Citi Investment Research Global Healthcare Conference
11. Alexza to Webcast Investor and Analyst Day Presentations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... (HealthDay News) -- When it comes to firearm deaths, ... States, while the District of Columbia has the highest, ... deaths from gun-related violence -- including murders, suicides and ... the study revealed. Hawaii,s rate was roughly three per ... the District of Columbia had the highest rate of ...
(Date:9/19/2014)... led by Medical College of Wisconsin (MCW) scientists has identified ... in rats, mice and in humans. The findings are published ... , Leah Solberg Woods, Ph.D., associate professor of pediatrics ... Wisconsin Research Institute, led the study and is the corresponding ... identified a gene called Tpcn2 in which a variant was ...
(Date:9/19/2014)... Top10BestSEOHosting.com today compares many professional Windows ... and Bluehost are the best suppliers of 2014. ... hosting (including VPS and cloud hosting) at affordable ... information. , HostMonster ( http://www.hostmonster.com/track/seohosts ) helps business ... fraction of the cost. As a top rated ...
(Date:9/19/2014)... patients with advanced, incurable cancer do not receive any ... this month at the ESMO 2014 Congress in Madrid, ... come at the same time as 15 new oncology ... being awarded the prestigious title of ,ESMO Designated Centre ... Dr Alexandru Grigorescu, medical oncology consultant at the Institute ...
(Date:9/19/2014)... 2014 Follow us on ... for detection and quantification of the presence of ... by steady expansion in immunodiagnostics and technological advancements ... systems market has evolved remarkably well over the ... diabetes, cardio-vascular ailments, infectious diseases, allergy and cancer, ...
Breaking Medicine News(10 mins):Health News:U.S. Gun Deaths Lowest in Hawaii, Highest in D.C. 2Health News:Top10BestSEOHosting.com: They Are Best Windows Web Hosting Suppliers Of 2014 2Health News:Patients with advanced, incurable cancer denied palliative care 2Health News:Patients with advanced, incurable cancer denied palliative care 3Health News:Patients with advanced, incurable cancer denied palliative care 4Health News:Growing Preference for Non-Invasive Diagnostics Spurs Growth in the Global Immunoassay Systems Market, According to New Report by Global Industry Analysts, Inc. 2Health News:Growing Preference for Non-Invasive Diagnostics Spurs Growth in the Global Immunoassay Systems Market, According to New Report by Global Industry Analysts, Inc. 3Health News:Growing Preference for Non-Invasive Diagnostics Spurs Growth in the Global Immunoassay Systems Market, According to New Report by Global Industry Analysts, Inc. 4
... By Amanda Gardner HealthDay Reporter , ... that derives fats and proteins from vegetable sources rather ... Comparing the two types of diets over two decades, ... reduced rates of death from cardiovascular disease and cancer, ...
... States must focus on conserving the use of antibacterial ... rising rates of antibiotic-resistant infections, according to an analysis ... of antibiotics is being depleted by resistance, which occurs ... no longer respond to widely-used treatments. Most proposals to ...
... The Endocrine Society released a new clinical practice guideline ... (CAH). The guideline features a series of evidence-based clinical ... guideline, published in the September 2010 issue of the ... JCEM ), a publication of The Endocrine Society, is ...
... methods, researchers at the University of California, San Diego ... spend significantly more time visually examining dynamic geometric patterns ... viewing pattern not found in either typical or developmentally ... that a preference for geometric patterns early in life ...
... psychotic disorders and living in urban areas appears to ... cities, according to a report in the September issue ... the JAMA/Archives journals. "There is a ... authors write as background in the article. "The clearest ...
... blood levels of chemicals used in the production of ... have elevated total and LDL cholesterol levels, according to ... of Pediatrics & Adolescent Medicine , one of the ... compounds known as perfluoroalkyl acidsincluding perfluorooctanoic acid (PFOA) and ...
Cached Medicine News:Health News:Low-Carb Diets Heavy on Meat May Raise Health Risks 2Health News:Pharmaceutical conservation key to slowing rise of antibiotic-resistant infections 2Health News:Pharmaceutical conservation key to slowing rise of antibiotic-resistant infections 3Health News:Experts recommend universal screening of newborns for congenital adrenal hyperplasia 2Health News:Visual pattern preference may be indicator of autism in toddlers 2Health News:Visual pattern preference may be indicator of autism in toddlers 3Health News:Study examines association between urban living and psychotic disorders 2Health News:Compounds in non-stick cookware may be associated with elevated cholesterol in children and teens 2
(Date:9/19/2014)... EASTON, Mass. , Sept. 19, 2014 /PRNewswire/ ... "Company") today announced it has received and approved ... Barozyme HT48 instruments and has begun to manufacture ... the first instrument will be ready for shipment ... be built and released at a rate of ...
(Date:9/19/2014)... 19, 2014 Aufgrund der ... äußerst erfolgreichen Serialisierungs-Countdown-Kalender aktualisiert, der jetzt auch die ... verfügbar unter pharmaserialisation.com , zeigt die Serialisierungsanforderungen ... in Kraft treten. Für international tätige ... um das "ob", sondern darum, "wann" sie die ...
(Date:9/19/2014)... and CAMBRIDGE, Mass. ... Inc. (PGDx), a provider of advanced cancer ... Medicines , a leader in discovering and developing ... today disclosed the first-ever comprehensive genomic study of ... deadly cancer of the female reproductive system, also ...
Breaking Medicine Technology:Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 2Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 3Pharma IQ stellt weltweite Serialisierungsfristen in seinen Countdown-Kalender 2014 - 2018 2First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 2First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 3First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 4
Produce clean 0.75 mm round hole without tissue tags. Serrated squeeze action handle....
Target illumination for day and night testing. Glare luminance distance. The Optec 3500 remote control offers flexible positioning during test administration. Each vision tester includes 12 tests sli...
... The CSV- lOOOHGT instrument provides standardized glare testing. ... Vectorvision test faces for the evaluation of glare ... is precisely calibrated to simulate two on-coming halogen ... feet. The glare level can be adjusted to ...
Ruler S/Steel....
Medicine Products: